FDA approves treatment to manage lung disease

The U.S. Food and Drug Administration has approved the use of nerandomilast to treat patients with idiopathic pulmonary fibrosis.

The approval followed positive results from two clinical trials demonstrating that adult patients who received the novel drug had lower declines in forced vital capacity compared with those who received placebo. Researchers reported that among the adverse events were nausea, dizziness, fatigue, headaches, diarrhea, vomiting, back pain, dizziness and decreased appetite.

Patients who are eligible for treatment should receive 18 milligrams of nerandomilast orally twice daily.

Read more: FDA

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.